Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Alicja J. Copik"'
Publikováno v:
Viruses, Vol 16, Iss 8, p 1270 (2024)
Natural killer (NK) cells can be effective immunotherapeutic anti-cancer agents due to their ability to selectively target and kill tumor cells. This activity is modulated by the interaction of NK cell receptors with inhibitory ligands on the surface
Externí odkaz:
https://doaj.org/article/5d77f5493d7548818ab809e97de35206
Autor:
Jeremiah L. Oyer, Tayler J. Croom-Perez, Md Faqrul Hasan, Javier A. Rivera-Huertas, Sarah B. Gitto, Joanna M. Mucha, Xiang Zhu, Deborah A. Altomare, Robert Y. Igarashi, Alicja J. Copik
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
NK cell therapeutics have gained significant attention as a potential cancer treatment. Towards therapeutic use, NK cells need to be activated and expanded to attain high potency and large quantities for an effective dosage. This is typically done by
Externí odkaz:
https://doaj.org/article/a1322c48c6044a24a3fa333918436d9b
Autor:
Jeremiah L. Oyer, Tayler J. Croom-Perez, Thomas A. Dieffenthaller, Liza D. Robles-Carillo, Sarah B. Gitto, Deborah A. Altomare, Alicja J. Copik
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
There is a great interest in developing natural killer (NK) cells as adoptive cancer immunotherapy. For off-the-shelf approaches and to conduct multicenter clinical trials, cryopreserved NK cells are the preferred product. However, recent studies rep
Externí odkaz:
https://doaj.org/article/29e98c27f36e4709aaf856cfeec9eaf2
Autor:
Sarah B. Gitto, Jordan M. Beardsley, Sai Preethi Nakkina, Jeremiah L. Oyer, Kathryn A. Cline, Sally A. Litherland, Alicja J. Copik, Amr S. Khaled, Na’im Fanaian, J. Pablo Arnoletti, Deborah A. Altomare
Publikováno v:
Cell Communication and Signaling, Vol 18, Iss 1, Pp 1-14 (2020)
Abstract Background While inflammation is associated with pancreatic cancer, the underlying mechanisms leading to cancer initiation are still being delineated. Eosinophils may promote or inhibit tumor growth, although the specific role in pancreatic
Externí odkaz:
https://doaj.org/article/182a76e644af4cc9a41cfff458d20fb4
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Cancer immunotherapy is a highly successful and rapidly evolving treatment modality that works by augmenting the body’s own immune system. While various immune stimulation strategies such as PD-1/PD-L1 or CTLA-4 checkpoint blockade result in robust
Externí odkaz:
https://doaj.org/article/0c7a2beb4393491b8fa66ac25df1f0d2
Publikováno v:
OncoImmunology, Vol 7, Iss 11 (2018)
Anti-PD-1/anti-PD-L1 therapies have shown success in cancer treatment but responses are limited to ~ 15% of patients with lymphocyte infiltrated, PD-L1 positive tumors. Hence, strategies that increase PD-L1 expression and tumor infiltration should ma
Externí odkaz:
https://doaj.org/article/a3ecc3d86615459fb3751b0f4a5bf805
Autor:
Md Faqrul Hasan, Tayler J. Croom-Perez, Jeremiah L. Oyer, Thomas A. Dieffenthaller, Liza D. Robles-Carrillo, Jonathan E. Eloriaga, Sanjana Kumar, Brendan W. Andersen, Alicja J. Copik
Publikováno v:
Cancers; Volume 15; Issue 10; Pages: 2712
Treatments targeting TIGIT have gained a lot of attention due to strong preclinical and early clinical results, particularly with anti-PD-(L)1 therapeutics. However, this combination has failed to meet progression-free survival endpoints in phase III
Autor:
Cristina Fernandez-Valle, Maria Clara Franco, Long-Sheng Chang, Fred F. Telischi, Xue Zhong Liu, Alicja J. Copik, Julia N. Soulakova, Rulong Shen, Rahul Mittal, Denise Yan, Olena Bracho, Christine T. Dinh, Sarah S. Burns, Stephani Klingeman Plati, Marisa A. Fuse
Neurofibromatosis type 2 (NF2) is a nervous system tumor disorder caused by inactivation of the merlin tumor suppressor encoded by the NF2 gene. Bilateral vestibular schwannomas are a diagnostic hallmark of NF2. Mainstream treatment options for NF2-a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e2082edda612e31101b4c151aaef003
https://doi.org/10.1158/1535-7163.c.6538786.v1
https://doi.org/10.1158/1535-7163.c.6538786.v1
Autor:
Cristina Fernandez-Valle, Maria Clara Franco, Long-Sheng Chang, Fred F. Telischi, Xue Zhong Liu, Alicja J. Copik, Julia N. Soulakova, Rulong Shen, Rahul Mittal, Denise Yan, Olena Bracho, Christine T. Dinh, Sarah S. Burns, Stephani Klingeman Plati, Marisa A. Fuse
All supplementary data - four figures and supplementary methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89058016f44c9a449071bff09a3eb168
https://doi.org/10.1158/1535-7163.22507780.v1
https://doi.org/10.1158/1535-7163.22507780.v1
Autor:
Deanna Deveson Lucas, Cornelia B. Landersdorfer, Jürgen B. Bulitta, Tae Hwan Kim, Dhruvitkumar S. Sutaria, Amy Wright, John D. Boyce, Arnold Louie, Alicja J. Copik, Brian T. Tsuji, Herbert P. Schweizer, Michael H. Norris, Miranda J. Wallace, Jeremiah Oyer, Carolin Werkman, Suresh Dharuman, Eric D. LoVullo, Beom Soo Shin, Yinzhi Lang, Xun Tao, Rossie H. Jimenez-Nieves, Brett A. Fleischer, Yuanyuan Jiao, Robert A. Bonomo, Venkataraman Balasubramanian, Kari B. Basso, Eunjeong Shin, Marianne Mégroz, George L. Drusano, Victoria C. Loudon-Hossler, Keisha C. Cadet, Nagakumar Bharatham, Jieqiang Zhou, Stephanie M. Reeve, Bartolomé Moyá, Nirav Shah, Alaa R. M. Sayed, Richard E. Lee
Publikováno v:
Clinical Pharmacology & Therapeutics. 109:1000-1020
Multidrug-resistant bacteria are causing a serious global health crisis. A dramatic decline in antibiotic discovery and development investment by pharmaceutical industry over the last decades has slowed the adoption of new technologies. It is imperat